公开(公告)号：US10564165B2

公开(公告)日：2020-02-18

申请号：US14850864

申请日：2015-09-10

Applicant: GENENTECH, INC.

Inventor： Lelia Delamarre ,  Patrick Lupardus ,  Ira Mellman ,  Mahesh Yadav ,  Suchit Jhunjhunwala ,  Jennie Lill

IPC: G01N33/68 ,  C12Q1/6886 ,  A61K39/00 ,  G01N33/569

Abstract: The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions.

公开(公告)号：US20160317632A1

公开(公告)日：2016-11-03

申请号：US15095985

申请日：2016-04-11

Applicant: GENENTECH, INC. ,  CONSTELLATION PHARMACEUTICALS, INC.

Inventor： Brian K. Albrecht ,  James Edmund Audia ,  Steven Bellon ,  Andrea Cochran ,  Alexandre Cote ,  Terry Crawford ,  Benjamin Fauber ,  Srimoyee Ghosh ,  Jean-Christophe Harmange ,  Georgia Hatzivassiliou ,  Hariharan Jayaram ,  Jeong Kim ,  Jose M. Lora ,  Steven Magnuson ,  Ira Mellman ,  Anthony F. Romero ,  Alexander M. Taylor ,  Vickie Tsui

IPC: A61K39/00 ,  A61K31/498 ,  G01N33/50 ,  A61K31/538

CPC classification number: A61K39/0011 ,  A61K31/498 ,  A61K31/538 ,  C07K14/475 ,  G01N33/5011

Abstract: The present invention relates to use of CBP/EP300 bromodomain inhibitors for the treatment of cancer.

Abstract translation: 本发明涉及CBP / EP300溴结构域抑制剂用于治疗癌症的用途。

公开(公告)号：US20160158360A1

公开(公告)日：2016-06-09

申请号：US14959221

申请日：2015-12-04

Applicant: Genentech, Inc.

Inventor： Sairy Hernandez ,  Ira Mellman ,  Jing Qing ,  Deepak Sampath

IPC: A61K39/395 ,  A61K45/06

CPC classification number: A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/76

Abstract: Compositions and methods for enhancing an immune response and treating cancer are provided. Compositions comprise PD-1 axis antagonists and HPK1 antagonists. PD-1 axis antagonists include PD-1 antagonists, PD-L1 antagonists, and PD-L2 antagonists. PD-1 axis antagonists can inhibit the binding of PD-L1 and/or PD-L2 to PD-1. HPK1 antagonists include compounds that inhibit the serine/threonine kinase activity of HPK1. Methods for enhancing an immune response or treating cancer comprise administering a PD-1 axis antagonist and a HPK1 antagonist, sequentially or simultaneously, to a subject in need thereof.

Abstract translation: 提供了增强免疫应答和治疗癌症的组合物和方法。 组合物包含PD-1轴拮抗剂和HPK1拮抗剂。 PD-1拮抗剂包括PD-1拮抗剂，PD-L1拮抗剂和PD-L2拮抗剂。 PD-1轴拮抗剂可以抑制PD-L1和/或PD-L2与PD-1的结合。 HPK1拮抗剂包括抑制HPK1的丝氨酸/苏氨酸激酶活性的化合物。 增强免疫应答或治疗癌症的方法包括将PD-1轴拮抗剂和HPK1拮抗剂依次或同时施用于有需要的受试者。

公开(公告)号：US20180280505A1

公开(公告)日：2018-10-04

申请号：US15885040

申请日：2018-01-31

Applicant: Genentech, Inc.

Inventor： Sairy Hernandez ,  Ira Mellman ,  Jing Qing ,  Deepak Sampath

IPC: A61K39/395 ,  C07K16/28

Abstract: Compositions and methods for enhancing an immune response and treating cancer are provided. Compositions comprise PD-1 axis antagonists and HPK1 antagonists. PD-1 axis antagonists include PD-1 antagonists, PD-L1 antagonists, and PD-L2 antagonists. PD-1 axis antagonists can inhibit the binding of PD-L1 and/or PD-L2 to PD-1. HPK1 antagonists include compounds that inhibit the serine/threonine kinase activity of HPK1. Methods for enhancing an immune response or treating cancer comprise administering a PD-1 axis antagonist and a HPK1 antagonist, sequentially or simultaneously, to a subject in need thereof.